SFX by Ex Libris Inc.

Title:	Recombinant Immunocytokines Targeting the Mouse Transferrin Receptor: Construction and Biological Activities
Source:	Bioconjugate Chemistry [1043-1802] Dreier, Torsten yr:1998

Basic

Full text

Full text available via American Chemical Society Journals

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Larkin, Kelly L. "Use of intravitreal rituximab for treatment of vitreoretinal lymphoma." British journal of ophthalmology 98.1 (2013): 99-103.
description	2.	Johannsen, M. "The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma." European journal of cancer 46.16 (2010): 2926-2935.
description	3.	Vawter, B P. "Human olfactory neuroepithelial cells: tyrosine phosphorylation and process extension are increased by the combination of IL-1beta, IL-6, NGF, and bFGF." Experimental Neurology 142.1 (1996): 179-94.
description	4.	Nishida, K. "Efficacy and Complications of Intravitreal Rituximab Injection for Treating Primary Vitreoretinal Lymphoma." Translational Vision Science & Technology 1.3 (2012): 1-1.
description	5.	Cunningham, Emmett T. "Treatment of chronic noninfectious uveitis in children-the trend toward tumor necrosis factor-alpha inhibition." Journal of AAPOS 17.5 (2013): 451-453.
description	6.	Turaka, Kiran S. "Vitreoretinal lymphoma: changing trends in diagnosis and local treatment modalities at a single institution." Clinical lymphoma, myeloma and leukemia 12.6 (2012): 412-417.
description	7.	Gebauer, M. "Combinatorial Design of an Anticalin Directed against the Extra-Domain B for the Specific Targeting of Oncofetal Fibronectin." Journal of Molecular Biology 425.4 (2012): 780-802.
description	8.	Pfaffen, S. "Tumour-targeting properties of antibodies specific to MMP-1A, MMP-2 and MMP-3." European journal of nuclear medicine and molecular imaging 37.8 (2010): 1559-1565.
description	9.	Krieg, C. "Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells." Proceedings of the National Academy of Sciences of the United States of America 107.26 (2010): 11906-11911.
description	10.	Pulido, Sujit S. "Rituximab for intraocular lymphoma." Retina 29.2 (2009): 129-32.
description	11.	Charles H. Lawrie et al, Charles H H. "Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma." British journal of haematology 141.5: 672-5.
description	12.	Fitsanakis, V. "Putative proteins involved in manganese transport across the blood-brain barrier." Human & experimental toxicology 26.4 (2007): 295-302.
description	13.	Schliemann, C. "Antibody-based targeting of the tumor vasculature." Biochimica et biophysica acta. Reviews on cancer 1776.2 (2007): 175-192.
description	14.	Kramer, K. "Recombinant antibodies for environmental analysis." Analytical and bioanalytical chemistry 377.3 (2003): 417-426.
description	15.	Itty, S. "Treatment of primary intraocular lymphoma (PIOL) has involved systemic, intravitreal or intrathecal chemotherapy and/or radiotherapy." Retina 29.3 (2009): 415-6.
description	16.	Weber, J. "The MicroRNA Spectrum in 12 Body Fluids." Clinical Chemistry 56.11 (2010): 1733-1741.
description	17.	"Rituximab-Associated Retinal Occlusive Vasculopathy: A Case Report and Literature Review." Ocular immunology and inflammation. 28.4: 622-625.
description	18.	Mansour, Ahmad M. "Combined intracorneal and subconjunctival bevacizumab injections for recurrent visual loss and intraocular hemorrhage from vascularized fibrous downgrowth." Case Reports in Ophthalmology 5.1 (2014): 28-33.
description	19.	Bravo Ljubetic, L. "Adalimumab therapy for refractory childhood uveitis." Journal of AAPOS 17.5 (2013): 456-459.
description	20.	Schwager, K. "The Immunocytokine L19-IL2 Eradicates Cancer When Used in Combination with CTLA-4 Blockade or with L19-TNF." Journal of investigative dermatology 133.3 (2013): 751-758.